ICAM1 and inflammation: Theoretically, ICAM-1 as a mediator of endothelial inflammation was increased in patients with confirmed COVID-19, because SARS-CoV-2 will trigger an inflammatory cascade in cells through its endothelial receptors, which were then known as cytokine storms [17].